| Serial Number | 98209814 |
| Word Mark | LEXEO |
| Filing Date | Wednesday, October 4, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Tuesday, September 30, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 4, 2025 |
| Goods and Services | House mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects for treatment therefor; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 13, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Lexeo Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10010 |
| Party Name | Lexeo Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10010 |
| Event Date | Event Description |
| Friday, May 24, 2024 | ASSIGNED TO EXAMINER |
| Friday, May 31, 2024 | NON-FINAL ACTION E-MAILED |
| Saturday, October 7, 2023 | NEW APPLICATION ENTERED |
| Friday, October 13, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, May 31, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, May 31, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 27, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 28, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, August 28, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, November 27, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, November 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, January 15, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 15, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, January 15, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 15, 2025 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 29, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 4, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 30, 2025 | SOU EXTENSION 1 FILED |
| Tuesday, September 30, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 30, 2025 | SOU EXTENSION 1 GRANTED |
| Wednesday, October 8, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, February 4, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 1, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |